Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Introducing the TechClusion Fund

Communication Service for the Deaf

CSD Social Venture Fund, a subsidiary of Communication for the Deaf, is proud to announce the launch of a new funding source for tech startups that prioritize inclusion and accessibility for deaf communities. The TechClusion Fund is a groundbreaking initiative that addresses a common oversight in technology development: accessibility. The fund was created with the intention of accelerating technology built by companies that create accessible products and services that benefit the Deaf community. Over the past 30 years, our society has experienced a rapid evolution in technological advancements. While these advancements generally improve our lives, we often see accessibility features added as an afterthought instead of being built into the original product design. This practice makes the user experience less than ideal for both those who do and do not use these features. “Accessible technology doesn’t just benefit Deaf communities,” explained Rosa Lee Timm, President of CSD Social Venture Fund. “When companies design their products with the needs of Deaf or disabled users in mind, they create a better experience for all users.” The TechClusion Fund was started with the intention of addressing these systemic and prevalent issues in tech by ensuring that entrepreneurs and developers are intentionally creating their products with all end-users in mind. “We expect that the impact of the TechClusion Fund will extend beyond the development of accessible products,” shared Greg Bland, Director of Business Development for CSD Social Venture Fund. “By focusing on startups who hope to have a positive impact on Deaf communities, we will see job creation and more opportunities for economic advancement for Deaf individuals.” Unlike CSD Social Venture Fund’s traditional VC funding, TechClusion is open to all tech-startups operating in the United States and not specifically Deaf-owned businesses. Applicants must demonstrate the following: How their work will positively impact Deaf communities. This can be through hiring Deaf and hard of hearing employees, Deaf ownership, or outlining how their product or service will contribute to deaf communities. A commitment to equitably hire Deaf, BIPOC Deaf, and other Deaf groups for various positions at levels of the company, including C-level positions, as the company grows. A commitment to both their company and TechClusion’s investment. For those who are interested in applying or learning more, you can visit CSD Social Venture Fund’s website or contact Rosa Lee Timm at svf@csdsvf.com for more information. CSD's Social Venture Fund is one of the only venture capital firms and incubators in the world supporting Deaf entrepreneurs and Deaf-owned and operated businesses. CSD SVF provides equity investments to Deaf-led businesses that exemplify CSD’s values: enhancing Deaf economic power, employing Deaf people, and creating social change. CSD SVF is committed to the success of each business, providing not only financial investment, but also access to tools and resources, enabling each Deaf-led business to thrive. Existing portfolio members include Mozzeria, National Deaf Therapy, DeafTax, Bus Door Films, Hands on Travel, Hotsy Totsy Haus, 4Legz All Natural Dog Treats and Lochiel Brewing. For more information, please visit https://csdsvf.com/ and follow us on Facebook, Twitter, Instagram, and LinkedIn. About Communication Service for the Deaf Communication Service for the Deaf (CSD) is the largest Deaf-led social impact organization in the world. For more than four decades, CSD has been a leader in creating and providing accessible and innovative solutions for the Deaf community. Today, CSD continues its work to create opportunities for personal and economic growth within the Deaf community, specifically addressing leadership and employment. For more information, please visit CSD and follow us on Facebook, Twitter, Instagram, and LinkedIn. Contact Details Communication Service for the Deaf Molly Miller +1 315-679-8948 mmiller@csd.org Company Website https://www.csd.org/

October 31, 2023 01:12 PM Eastern Daylight Time

Image

Stay Ahead of Cough, Cold and Flu Season

YourUpdateTV

As the colder months approach, millions of people across the nation are gearing up for the inevitable cough, cold and flu season. Recently, Emergency Room Physician, Dr. Darria Long, conducted a satellite media tour to share tips and advice on how to stay healthy and prepared. A video accompanying this announcement is available at: https://youtu.be/5yVw5AWHbXw As the colder months approach, millions of people across the nation are gearing up for the inevitable cold and flu season. The cough, cold and flu season is marked by a significant increase in the spread of respiratory viruses, which can lead to a surge in illnesses and medical visits. Advanced preparation provides an opportunity to ensure that necessary supplies, medications, and remedies are readily available. Having essential items, like Mucinex 12H, on hand before symptoms strike can make a significant difference. Mucinex 12-Hour relieves chest congestion and thins and loosens mucus. It is clinically proven to last up to 12 hours and provide relief for your chest congestion and make coughs more productive. One dose of Mucinex 12-Hour lasts 3 times longer than other 4-HR medicines helping individuals manage discomfort effectively and get back to their daily activities sooner. Always use over-the-counter products as directed. If symptoms persist, you should contact your healthcare professional and get checked out if deemed necessary. Taking better care of ourselves during the cough, cold and flu season is paramount to staying healthy and minimizing the risk of falling ill. Key preventative measures like washing your hands often, covering your nose and mouth with a tissue when you cough or sneeze, and sneezing into your elbow if you don’t have a tissue are extremely effective at preventing the spread of germs. Additionally, maintaining a healthy lifestyle is crucial. Adequate sleep, a balanced diet rich in fruits and vegetables, regular physical activity, and managing stress contribute to a strong immune system. Staying hydrated by drinking plenty of fluids, particularly water and herbal teas, can also help keep our respiratory tract moist and better able to fend off viruses. For more information on how to take care of yourself this cold and flu season, visit Mucinex.com. You can stop by Walmart, Target, your local pharmacy or food retailer to buy Mucinex now ahead of this cough and cold season. BIO: Dr. Darria Long, MD Dr. Darria Long leverages the best of science, to make our lives healthier, better… and easier. By combining her life’s work as an Emergency Room physician and being a mom of two – Dr. Darria has become the nation’s ‘making life better for women’ doctor by helping individuals pave ways to stay present and remain healthy during times of constant distractions and high stress. With a website devoted to distilling health headlines and creating a thriving lifestyle, Dr. Darria shares simple, evidence-based (from western, eastern, and integrative medicine) advice on physical and mental wellness, and the health guidance you’d expect and trust from a close friend. A favored national TV contributor and national bestselling author of Mom Hacks, Dr. Darria is also a TED speaker “How to triage your life like an ER doctor,” and Clinical Assistant Professor at the University of Tennessee. She received her training in emergency medicine at Yale School of Medicine and her MBA from Harvard Business School. A featured regular on CNN, Headline News, NBC, Interview Healthline, Hallmark, Lifetime, Dr. Oz, Thrive Global, Atlanta Small Business Network, Parenting for the future, and many others. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 31, 2023 01:04 PM Eastern Daylight Time

Video

PathAI Announces Research Presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions with end-to-end central pathology and histology services, today announced it will present research underscoring the efficacy of PathExplore’s human interpretable features (HIFs) through three poster presentations at the Society for Immunotherapy of Cancer’s 38 th Annual Meeting on November 1-5 in San Diego, CA. The posters showcase how PathExplore provides high-resolution characterization of the tumor microenvironment (TME) through a standardized panel of HIFs derived from H&E whole slide images across multiple cancer types. Additionally, Incendia Therapeutics will present two posters reporting results that were generated utilizing PathExplore. “Building upon past publications and presentations, we continue to see the utility for histological features of the tumor microenvironment to further our understanding of disease biology, patient prognosis, and therapeutic response, which ultimately may lead to the discovery and implementation of novel biomarkers to advance precision medicine,” explained Mike Montalto, Ph.D., Chief Scientific Officer, PathAI. All three posters demonstrate the correlation between specific HIFs and established molecular measurements of the TME (e.g., gene expression profiles of specific cell populations), as well as specific HIFs and complex molecular signatures (e.g., immune phenotypes) which could better aid in the identification of patients eligible for targeted therapies, or result in the identification of new histology-based biomarkers. Quantifying the effect of microsatellite instability and mismatch repair deficiency on the tumor microenvironment (Poster 73) In this research, PathAI investigated the potential to predict and compare microsatellite stability and mismatch repair subtypes in colorectal and endometrial cancers utilizing PathExplore HIFs. The findings suggest MSS/dMMR tumors may warrant consideration for immunotherapy due to their TME’s similarity to microsatellite instability-high (MSI-H) and tumor mutation burden-high (TMB-H) solid tumors and AI-powered analysis of H&E WSI presents a more accessible and scalable method than current dMMR testing options. This poster will be presented by Judy Chen and Shima Nofallah on Friday, November 3 rd. Poster hall hours are 9 a.m. to 7 p.m. PT. Quantification of tumor infiltrating lymphocytes (TILs) from pathology slides reflects molecular immune phenotypes (Poster 122) In this research, PathAI deployed its PathExplore products on H&E WSI across eight cancer indications to extract HIFs quantifying the TME, including features that represent TIL fractions, densities, and distributions. Analysis revealed statistically significant correlations between TIL-associated HIFs with gene expression of known lymphocyte markers, as well as immune signature scores such as lymphocyte infiltration. These results show the predictive power that TIL-associated HIFs have for identifying immune phenotypes, as well as a promising direction for the discovery of histology-based immune biomarkers. This poster will be presented by Judy Shen on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Deep learning models identify key tumor microenvironment features associated with genetic signatures of UV metagenesis and alkylating agent treatment in melanoma (Poster 110) In this research, PathAI used PathExplore HIFs to investigate the association between TME features and mutational signatures indicative of UV mutagenesis, as well as alkylating agents-induced mutations. The results suggest that quantifying a tumor’s tissue and cellular composition can reveal meaningful information regarding the underlying mutation-driven or treatment-induced changes in the TME, which may have implications for therapy selection. This poster will be presented by Shima Nofallah on Saturday, November 4 th. Poster hall hours are 9 a.m. to 8:30 p.m. PT. Incendia Therapeutics (formerly known as Parthenon Therapeutics) posters In addition to the posters above, Incendia Therapeutics will present two posters on Friday, November 3 rd reporting results that were generated utilizing PathExplore. One poster (Poster 1287) compares PathExplore HIFs to mIF features and concluded that "TME models are a robust tool to distinguish tissue and cell features from H&E slides, comparable to mlF image analysis, but requiring less effort, time, and expense." In the second (Poster 1497), Incendia Therapeutics leveraged HIFs quantifying lymphocyte densities across cancer epithelium, cancer stroma, and the epithelial-stromal interface (ESI) to characterize barriers to lymphocyte entry into the cancer epithelium across immune phenotypes. More information on these posters can be found at https://www.incendiatx.com Please visit the PathAI booth, 615, to learn more and meet the team, or email us at bd@pathai.com. About PathAI PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI, which is headquartered in Boston, MA, and operates a CAP/CLIA-certified laboratory in Memphis, TN, is proud to have a team of 600+ innovative thinkers from around the globe. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

October 31, 2023 10:00 AM Eastern Daylight Time

Cardio Diagnostics Leverages AI To Combat Cardiovascular Disease

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardiovascular disease is the leading cause of death worldwide, accounting for nearly 18 million deaths annually. That amounts to about one-third of all global deaths. Driven by epigenetics and artificial intelligence, what is being referred to as Precision Cardiovascular Medicine could help alleviate the burden of heart disease on patients worldwide. Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and detection more precise, is a potential leader in this developing field of medicine. AI-Driven Currently, the risk for cardiovascular disease is assessed using two common lipid-based clinical tests: the Framingham Risk Score and the ASCVD Pooled Cohort Equation. The disease is then detected using several tests, including exercise ECG, coronary computed tomography angiography, cardiac catheterization, cardio magnetic resonance imaging, single-photon emission computed tomography and echocardiography. Cardio Diagnostics was formed to improve detection through further developing and commercializing clinical tests by leveraging artificial intelligence-driven technology to combat cardiovascular disease. With the goal of becoming one of the leading medical technology companies for improving prevention, detection and treatment of cardiovascular disease, the company has developed four patented/patent-pending and proprietary solutions. The first is Cardio Diagnostics’ coronary heart disease risk assessment tool Epi+Gen CHD, a test that predicts the three-year risk for a coronary heart disease (CHD) event – mainly heart attacks. Powered by AI-driven integrated genetic-epigenetics, the tool enables more effective clinical decision-making and earlier interventions. Along with improved survival, the company reports that the tool is associated with up to $42,000 in cost savings per quality-adjusted life year. The second product developed using Cardio Diagnostics’ AI-driven Integrated Genetic-Epigenetic Engine is PrecisionCHD, and the company reports that it is the only epigenetics-based coronary heart disease detection test in the world. A sensitive and non-invasive alternative to exercise and nuclear stress tests, PrecisionCHD is a blood test where a blood sample can be collected at home or in provider settings without the need to wait weeks or months to get tested or the need for fasting or exposure to radiation. Cardio Diagnostics says this test has demonstrated strong clinical value with 80% sensitivity for men and 76% sensitivity for women, compared to the much lower rates of 45% to 68% using exercise ECG, which measures the electrical activity of the heart during physical activity. Cardio Diagnostics’ Actionable Clinical Intelligence platform offers new epigenetic and genetic insights to clinicians prescribing the Epi+Gen CHD and PrecisionCHD tests, while CardioInnovate360 is a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases. These solutions can potentially help address the needs of all major healthcare stakeholders. Easing The Burden Cardiovascular disease is a burden on all major stakeholders, including patients, providers, insurers and employers, who can face increased healthcare costs due to heart disease as employees with cardiovascular disease have medical bills that are over twice as high as those without the condition. Additionally, heart disease accounts for about a quarter of all emergency room visits related to chest pain according to the National Center for Biotechnology Information, straining hospital resources and emergency departments that see the sickest of patients. Globally, cardiovascular disease is expected to result in a cumulative output loss of $47 trillion from 2011 to 2030 due to medical costs and productivity losses, according to data compiled by Cardio Diagnostics. While cardiovascular disease is the leading cause of death worldwide, it is in fact highly preventable, with WHO data suggesting that 80% of premature heart attacks and strokes are preventable. That means these costs can be avoided, too. Cardio Diagnostics seems well-positioned to leverage its scalable tests around the world to aid in reducing the incidence of heart attacks and other CHD events. Between their robust product pipeline with tests across the CVD continuum from heart attacks to heart failure combined with strong partnerships with key healthcare stakeholders, there is a defined path to reduce the global impact of heart disease. By proactively identifying and entering multiple international markets to drive global access to Cardio’s technologies, the company seeks to diversify the risks of depending on a single national market and build a sustainable global strategy. This worldwide focus, coupled with a presence in diverse markets, has placed Cardio Diagnostics among the leaders in this growing field of artificial intelligence-powered medicine. For more information on Cardio Diagnostics, visit their website Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website http://www.cardiodiagnosticsinc.com/

October 31, 2023 09:15 AM Eastern Daylight Time

How Rexis Biotech Aims To Become The Nvidia Of The Consumer Products Industry

Rexis Biotech

By Meg Flippin, Benzinga Click here to learn more about Rexis Systems’ crowdfunding raise, and how to invest Cannabis is going mainstream as more states legalize the leafy herb. That's spawning a multi-billion-dollar market for CBD and THC products, with manufacturers putting it in everything from candy to drinks. The cannabis-infused beverage category in particular is growing in popularity as people look for healthier ways to get a buzz. Last year, the cannabis drink market was valued at $0.4 billion. By 2032, it is projected to reach $8.3 billion at a 37.7% CAGR over 2023-2032. These drinks promise to give consumers a smoother, gentler taste with few calories and zero hangover in the morning. Rexis Biotech Inc., the biotech out of Delaware, is taking the cannabis-infused beverage market to the next level with its proprietary Fused Polymorph Nano Fiber Technology™ that enhances the benefits and effects of cannabis in drinks. The current cannabis-infused drinks on the market do provide a new experience to consumers, but there are some limitations. For starters, the body can’t efficiently absorb most plant-based ingredients like CBD, THC and caffeine. As a result, consumers typically only receive 10% or less of the ingredient in their system. It also takes longer to absorb into the bloodstream, usually 45 to 90 minutes, when using oil-based infusions. These tend to give more of an edible high, as they are processed during first-pass digestion, versus the smoking high that using nanotechnology is supposed to create. Up until now, nanoemulsions have been the go-to solution to solve for faster onset, but emulsions tend to be unstable, easily losing 30% efficacy within the first three months. On top of that, they often leave a bitter or oily aftertaste in your mouth. Rexis Enhances The Benefits Rexis Biotech reports that its proprietary drug delivery platform eliminates those undesirable aspects of nanoemulsions, allowing them to create a lineup of Hemp Delta-9 THC-infused beverages that both taste amazing and enhance the consumer experience. Squared, the first beverage out of the gate for Rexis, is a lineup of better-for-you-sodas that are both delicious and nutritious. Available in a variety of flavors from their Classic Orange Pop that tastes exactly like an Orange Crush to their High Spirits Awards-winning Sparkling Grapefruit, these cannabis-infused beverages onset in about 10-15 minutes and provide a reliable effect that’s closer to the dosage on the can. Rexis says it is able to achieve that thanks to its fast-acting nano fiber technology which enables the drink to quickly absorb through the buccal membranes in the mouth versus having to go through first-pass digestion like traditional edibles. This allows the body to absorb and process the Hemp Delta-9 THC faster and more effectively. Squared beverages are also formulated to offset in about an hour – a key differentiator. It puts consumers in the driver’s seat regarding how much and how long they want to feel the effects. Squared Is Just The Beginning Rexis is demonstrating its nanotechnology with the launch of Squared, but its vision is much bigger. It wants to share its technology, aiming to be the Nvidia Corp. (NASDAQ: NVDA) or Intel Corp. (NASDAQ: INTC) of the consumer products industry. It envisions a world where brands license Rexis’s nanotechnology to enhance everything from drinks to food. Its partnership with 3Chi, Inc., one of the world’s largest hemp-derived consumer packaged goods manufacturers and retailers, underscores how it’s making that ambition a reality. Functional foods and beverages “Powered by Rexis” will be sold via their national distribution network, Wicked Smart Food Company, and they expect it to drive revenues of $24.6 million over the next three years. “Rexis separates itself from the competition with its technology. Their Fused Polymorph Nano Fiber is several steps above anything else that's in the marketplace right now. The quality of product that we have gotten from them is unsurpassed,” Justin Journay, 3Chi CEO, said when the deal was announced in July. The cannabis-infused beverage market seems to be taking off, and Rexis wants to be a leader. As more states legalize it and consumers clamor for healthier and tastier alternatives, Rexis is betting its proprietary nanotechnology will become the engine that drives these beverages like Intel’s chips power PCs. Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in the Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Ryan Erving ryan@rexissystems.com Company Website https://www.rexissystems.com

October 31, 2023 09:15 AM Eastern Daylight Time

Evgen Pharma "delighted" with cash position after promising first half

Evgen Pharma PLC

Evgen Pharma PLC (AIM:EVG) CEO Dr Huw Jones and new CFO Toni Hanninen speak to Thomas Warner from Proactive after the clinical stage drug development company announced its interim results for the six months to 31 September 2023. Dr Jones gives an overview of how Evgen has been performing on the operational side, highlighting clinical progress, the successful receipt of some new grant funding as well as changes to the board and to the executive team with the hiring of Toni Hanninen in late summer. Hanninen gives an overview of how Evgen performed financial during the reporting period, noting that there were no nasty surprises during the six months and that the company's cash runway of £3.7mln currently runs to the end of 2024. He goes on to say that he is "very very delighted" with the length of the runway given the financial challenges many of Evgen's peers are currently facing. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

October 31, 2023 06:43 AM Eastern Daylight Time

Video

News Release

Medicus Pharma CEO rings opening bell at the Toronto Stock Exchange

Medicus Pharma

Medicus Pharma executive chairman and CEO Dr Raza Bokhari joined Steve Darling from Proactive fresh from ringing the opening bell at the Toronto Stock Exchange. This after the company recently listed its common shares on the TSX Venture exchange under the ticker MDCX. Medicus Pharma is dedicated to accelerating novel life sciences and biotechnology companies by advancing them through FDA-approved clinical trials. The company specializes in de-risking clinical-stage assets through clinical development and eventual commercialization. Medicus Pharma has a subsidiary called Skinject, which is focused on commercializing a novel, non-invasive treatment for basal cell and squamous cell skin cancer. Skinject employs a patented dissolvable microneedle patch to deliver a chemotherapeutic agent that targets and eradicates tumor cells effectively. The company recently welcomed Dr Huma Qamar as its chief scientific officer and head of R&D Program. Dr Qamar brings a wealth of experience in the clinical research field, having worked with prestigious institutions such as Yale University, Harvard University, and the University of Pennsylvania. Medicus Pharma's listing on the TSX Venture Exchange represents a significant step forward for the company as it continues its mission to advance innovative therapies and treatments in the field of life sciences and biotechnology. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:31 PM Eastern Daylight Time

Video

News Release

Marizyme Inc CEO releases corporate update including details of key progress on DuraGraft

Marizyme Inc

Marizyme Inc CEO David Barthel joined Steve Darling from Proactive to provide an exciting update on the remarkable progress that the company has achieved in recent months. Among the standout developments is the approval received from the US Food and Drug Administration for its groundbreaking product, DuraGraft. DuraGraft is a first-in-class vascular conduit solution that has received FDA clearance, marking a significant milestone for Marizyme. This innovative product is specifically indicated for use in adult patients undergoing Coronary Artery Bypass Grafting (CABG) surgeries. Its primary purpose is to facilitate the flushing and storage of saphenous vein grafts employed in CABG procedures, offering a cutting-edge solution to enhance patient outcomes in cardiac surgery. One notable aspect of Marizyme's progress is the growing acceptance of DuraGraft in both Europe and Asia. The company has achieved impressive sales figures, with a total of 1,131 DuraGraft kits shipped so far this year. This is a remarkable increase compared to the 485 DuraGraft kits shipped in the previous year, underscoring the product's traction and demand in the international market. In summary, Marizyme, under the leadership of CEO David Barthel, is making significant strides in the medical industry. The FDA approval of DuraGraft and its increasing adoption in international markets signify the company's commitment to advancing medical technologies that improve patient outcomes. As Marizyme continues to expand its reach and forge new partnerships, it is poised for continued growth and success in the years ahead. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:23 PM Eastern Daylight Time

Video

News Release

BioHarvest Sciences closes first tranche of financing bringing in C$11.78M to Treasury

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share some exciting developments. The company has achieved a major milestone by successfully closing the first tranche of its financing, raising nearly C$12 million, even in the face of challenging market conditions. This accomplishment underscores the significant investor confidence in BioHarvest's strategic vision and the strength of its management team. The capital raised through this financing round will play a pivotal role in advancing several key initiatives within BioHarvest Sciences. One of the notable areas of focus is new product development and expansion. BioHarvest has ambitious plans to expand its product range, moving from a single SKU to ten SKUs spanning five different categories. Leveraging its advanced scientific capabilities, proven efficacy, and exceptional taste, the company is poised to make a significant impact in these markets. The eagerly awaited flagship product, a revolutionary coffee offering, is slated to disrupt the market starting in December. Geographical expansion is another crucial aspect of BioHarvest's growth strategy. With recent approval from Health Canada, the company is gearing up to enter the Canadian market, further extending its global footprint. Additionally, BioHarvest is accelerating clinical trials across various domains, positioning itself for substantial growth over the next 12 to 24 months. These clinical trials will not only underscore the efficacy of their products but also enhance their credibility and market presence. Despite the challenges posed by the current market conditions, BioHarvest remains unwavering in its commitment to the safety of its employees and the consistent delivery of high-quality products. The company's focus for the remainder of 2023 includes robust marketing initiatives and the highly anticipated launch of its innovative coffee product, aimed at revitalizing the stagnant decaffeinated coffee market. Contact Details Proactive Investors Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 30, 2023 03:18 PM Eastern Daylight Time

Video

1 ... 51 52 53 54 55 ... 275